Project 2 will expand our knowledge of FSHD biomarkers to enable identification of FSHD disease genes and genetic and epigenetic mechanisms responsible for FSHD muscle pathology, and facilitate pre-clinical studies to develop FSHD therapeutics.
In Aim 1, biomarkers for FSHD will be identified and validated using whole transcriptome sequencing (RNA-seq) and qRT-PCR analyses of muscle and myogenic cells from affected and unaffected subjects in FSHD family cohorts and in nonmanifesting carriers. Our large collection of muscle and cells available in the Cell Core will enable statistically powered studies to identify quantitative differences in the expression of coding and non-coding RNAs and splicing variants and candidate modifiers of disease severity, also being investigated in Project 1 by exome sequencing. The expression and functions of candidate disease biomarkers and modifier genes and their encoded proteins will be investigated in FSHD cells (Aim 1) and humanized mouse xenograft models (Project 3), and by using morpholino antisense inhibition to evaluate their functions in FSHD pathophysiology (Aim 3).
Aim 2 will investigate epigenetic and regulatory mechanisms controlling the expression of DUX4-fl and non-coding RNAs transcribed from the D4Z4 FSHD disease locus. Investigations focus on nonmanifesting carriers and unaffected members of FSHD families to test the hypothesis that disruptions in the DNA methylation status of the D4Z4 locus are early modifiers of genetic and regulatory disruptions leading to FSHD disease.
Aim 3 is a collaboration with our industry partner, Genzyme, to develop antisense oligo morpholino technology for investigating the disease functions of DUX4-fl and other candidate FSHD disease genes identified in Aim 1. The initial objectives are to develop and validate DUX4-fl morpholinos for RNA-seq studies to identify downstream targets of DUX4-fl regulation in FSHD cells as candidate FSHD disease genes. Cell morpholino studies will enable use of morpholinos in pre-clinical drug development studies in humanized mouse xenograft models in Project 3 to investigate the roles of DUX4-fl and other candidate disease genes in FSHD muscle pathophysiology.

Public Health Relevance

A complete molecular signature of FSHD disease provides biomarker tools for investigating and understanding the underlying genetic, epigenetic and pathophysiological mechanisms responsible for FSHD muscle disease, for development therapeutics in pre-clinical studies, and for monitoring efficacy of therapeutic agents in clinical trials

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54HD060848-07
Application #
8621140
Study Section
Special Emphasis Panel (ZNS1-SRB-S (57))
Project Start
Project End
Budget Start
2013-09-16
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$285,541
Indirect Cost
$100,888
Name
University of Massachusetts Medical School Worcester
Department
Type
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Sakellariou, Paraskevi; O'Neill, Andrea; Mueller, Amber L et al. (2016) Neuromuscular electrical stimulation promotes development in mice of mature human muscle from immortalized human myoblasts. Skelet Muscle 6:4
Chen, Jennifer Cj; King, Oliver D; Zhang, Yuanfan et al. (2016) Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics. Mol Ther 24:1405-11
Henninger, Nils; Bouley, James; Sikoglu, Elif M et al. (2016) Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1. Brain 139:1094-105
Jones, Takako I; King, Oliver D; Himeda, Charis L et al. (2015) Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy. Clin Epigenetics 7:37
Homma, Sachiko; Beermann, Mary Lou; Boyce, Frederick M et al. (2015) Expression of FSHD-related DUX4-FL alters proteostasis and induces TDP-43 aggregation. Ann Clin Transl Neurol 2:151-66
Moyer, Adam L; Wagner, Kathryn R (2015) Mammalian Mss51 is a skeletal muscle-specific gene modulating cellular metabolism. J Neuromuscul Dis 2:371-385
Huh, Yang Hoon; Noh, Minsoo; Burden, Frank R et al. (2015) Sparse feature selection identifies H2A.Z as a novel, pattern-specific biomarker for asymmetrically self-renewing distributed stem cells. Stem Cell Res 14:144-54
Lek, Angela; Rahimov, Fedik; Jones, Peter L et al. (2015) Emerging preclinical animal models for FSHD. Trends Mol Med 21:295-306
Zhang, Yuanfan; King, Oliver D; Rahimov, Fedik et al. (2014) Human skeletal muscle xenograft as a new preclinical model for muscle disorders. Hum Mol Genet 23:3180-8
Jones, Takako I; Yan, Chi; Sapp, Peter C et al. (2014) Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing. Clin Epigenetics 6:23

Showing the most recent 10 out of 23 publications